Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00269906
Status:
COMPLETED
Last Update Posted:
2015-05-25
First Post:
2005-12-22
Brief Title:
A Study Evaluating the Efficacy and Safety of Abciximab an Anti-Platelet Therapy in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
Sponsor:
Centocor Inc
Organization:
Centocor Inc
Study Overview
Official Title:
Chimeric Anti-Platelet Therapy Abciximab in Unstable Angina Refractory to Standard Medical Therapy Trial CAPTURE
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of abciximab an anti-platelet therapy versus placebo in patients with unstable angina who are not responding to standard medical therapy and who are eligible for coronary angioplasty
Detailed Description:
This is a randomized placebo-controlled study to evaluate the safety and efficacy of abciximab an anti-platelet therapy in patients with unstable angina who are not responding to standard medical therapy and who are eligible for coronary angioplasty The primary outcomes of the study include any of the following within 30 days the number of deaths from any cause myocardial infarctions or the number of recurrent ischemic events requiring urgent intervention such as a coronary artery bypass surgery repeat coronary angioplasty coronary stent placement or intra-aortic balloon pump Please see attached results
Patients will be treated with abciximab or matching placebo
Patients will be treated with abciximab or matching placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None